An AllTrials project

NCT03768089: A reported trial by Vertex Pharmaceuticals Incorporated

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT03768089
Title A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Results Status Reported
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date March 20, 2018
Completion date May 3, 2019
Required reporting date May 3, 2022, midnight
Actual reporting date April 29, 2022
Date last checked at ClinicalTrials.gov Dec. 12, 2025
Days late None